Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Angelo de Claro

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.
Pediatric Blood & Cancer|September 8, 2020
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patientsMargret Merino, Nicholas Richardson, Gregory Reaman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric CancerSandra J Casak, Yiming Zhang, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell LymphomaNajat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, et al.
The American Journal of Pathology|May 10, 2011
Hematopoietic Fas deficiency does not affect experimental atherosclerotic lesion formation despite inducing a proatherogenic stateR Angelo de Claro, Xiaodong Zhu, Jingjing Tang, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018Nadia Howlader, Elad Sharon, Manami Bhattacharya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Plos One|March 11, 2011
Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsisAkiko Iwata, R Angelo de Claro, Vicki L Morgan-Stevenson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2004
Differences in F36VMpl-based in vivo selection among large animal modelsRobert E Richard, R Angelo De Claro, James Yan, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.
Pediatric Blood & Cancer|September 8, 2020
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patientsMargret Merino, Nicholas Richardson, Gregory Reaman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric CancerSandra J Casak, Yiming Zhang, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell LymphomaNajat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, et al.
The American Journal of Pathology|May 10, 2011
Hematopoietic Fas deficiency does not affect experimental atherosclerotic lesion formation despite inducing a proatherogenic stateR Angelo de Claro, Xiaodong Zhu, Jingjing Tang, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018Nadia Howlader, Elad Sharon, Manami Bhattacharya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Plos One|March 11, 2011
Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsisAkiko Iwata, R Angelo de Claro, Vicki L Morgan-Stevenson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2004
Differences in F36VMpl-based in vivo selection among large animal modelsRobert E Richard, R Angelo De Claro, James Yan, et al.
Pageof 6